Skip to main content

Antibody therapy against coronavirus (COVID-19)

Objective

ATAC aims at developing passive immunotherapy against COVID-19. Human antibodies will be obtained from blood of CoV-recovered donors from China and Italy with three independent approaches: polyclonal gamma-globulins, B cell monoclonals and phage libraries. Antibodies will be characterized by rapid experimental and computational work, optimized, produced and tested in consultation with EMA to ensure prompt embedding of regulatory aspects.

The partners have outstanding experience in all aspects of the project, collaborated previously and worked on antibody therapy for diseases including SARS and MERS-CoV. Reagents and experienced personnel are already available ensuring quick and efficient progress, with initial deliverables within 3 months.

Besides providing a lead human antibody candidate for therapy, ATAC will rapidly disseminate results to help respond to the current COVID-19 epidemic. Results of the 2 years project will also further our understanding of CoV neutralization, contributing to future vaccination and therapeutic strategies.

The team includes the Karolinska Institutet (SE, Pan-Hammarström and Hammarström, coordinators), the Institute for Research in Biomedicine (CH, Varani and Robbiani); the Joint Research Centre- European Commission (BE, Calzolai); Technische Universität Braunschweig (DE, Hust) and Policlinico San Matteo (IT, Baldanti). The partners’ outstanding expertise is attested by high impact publications on antibody treatment for emerging infectious diseases.

Field of science

  • /medical and health sciences/health sciences/infectious disease/RNA virus/coronavirus

Call for proposal

H2020-SC1-PHE-CORONAVIRUS-2020
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

KAROLINSKA INSTITUTET
Address
Nobels Vag 5
17177 Stockholm
Sweden
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 755 396,25

Participants (4)

FONDAZIONE PER L ISTITUTO DI RICERCA IN BIOMEDICINA
Switzerland
EU contribution
€ 1 435 025
Address
Via Vincenzo Vela 6
6500 Bellinzona
Activity type
Research Organisations
JRC -JOINT RESEARCH CENTRE- EUROPEAN COMMISSION
Belgium
EU contribution
€ 198 545
Address
Rue De La Loi 200
1049 Brussels
Activity type
Research Organisations
TECHNISCHE UNIVERSITAET BRAUNSCHWEIG
Germany
EU contribution
€ 267 323,75
Address
Universitaetsplatz 2
38106 Braunschweig
Activity type
Higher or Secondary Education Establishments
FONDAZIONE IRCCS POLICLINICO SAN MATTEO
Italy
EU contribution
€ 338 750
Address
Viale Golgi 19
27100 Pavia
Activity type
Research Organisations